News
Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension
– Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need
Kiel, GERMANY, September 8, 2025 – tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that its long-standing collaboration partner Stanford University has been awarded a US$ double-digit million grant from the National Institutes of Health (NIH) – National Heart Lung and Blood Institute (NHLBI) – the Lung Division, to fund a U.S. Phase II trial of Tiprelestat for the treatment of Pulmonary Arterial Hypertension (PAH). Read more…
BellaSeno Establishes High-Profile Clinical Advisory Board
— Leading international experts to support clinical development of BellaSeno´s pioneering resorbable breast implants
— Pivotal clinical trial to be initiated shortly
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has established a Clinical Advisory Board consisting of seven renowned key opinion leaders (KOLs) in the fields of clinical breast reconstruction and plastic surgery. Read more…
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
— Funding combines equity investment and convertible loan
— Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody
— Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs
— Thomas Hecht has joined Board of Directors
Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has raised a total of CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a capital increase and a convertible loan of CHF 15 million, respectively. The funds are provided by Mabylon’s existing private investors, with the major investment coming from former management and board members of Roche. Read more…
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
- European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)
- Designation is paving the way for safer long-term therapy
- MP1032 has demonstrated ability to preserve muscle function and reduce inflammation without disrupting normal cellular processes
Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). Read more…